Creo Medical Group PLC (LON:CREO – Get Free Report) insider Craig Jonathan Gulliford purchased 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were purchased at an average price of GBX 14 per share, for a total transaction of £875.
Creo Medical Group Stock Up 0.1%
Shares of CREO stock traded up GBX 0.01 during trading hours on Monday, hitting GBX 14.57. 1,405,552 shares of the company’s stock traded hands, compared to its average volume of 871,779. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20. The stock’s fifty day simple moving average is GBX 13.18 and its two-hundred day simple moving average is GBX 12.90. Creo Medical Group PLC has a 12-month low of GBX 9.52 and a 12-month high of GBX 18.50. The stock has a market cap of £70.81 million, a price-to-earnings ratio of 14.57 and a beta of 1.62.
Creo Medical Group (LON:CREO – Get Free Report) last posted its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) earnings per share for the quarter. Creo Medical Group had a net margin of 88.33% and a return on equity of 9.56%. The company had revenue of GBX 600 million for the quarter. On average, analysts expect that Creo Medical Group PLC will post -10.0800005 EPS for the current year.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on CREO
About Creo Medical Group
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.
Featured Stories
- Five stocks we like better than Creo Medical Group
- This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
- These 3 Stocks Offer Investors Exposure to the Functional Beverage Boom
- Alcoa’s $4.1 Billion South32 Deal: Opportunity Behind the 9% Drop
Receive News & Ratings for Creo Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creo Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
